CN110664903A - Composition with blood fat reducing function and preparation method and application thereof - Google Patents
Composition with blood fat reducing function and preparation method and application thereof Download PDFInfo
- Publication number
- CN110664903A CN110664903A CN201910942769.8A CN201910942769A CN110664903A CN 110664903 A CN110664903 A CN 110664903A CN 201910942769 A CN201910942769 A CN 201910942769A CN 110664903 A CN110664903 A CN 110664903A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- ethanol
- water
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 20
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 20
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 20
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 20
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 239000000843 powder Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 29
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 23
- 241000180649 Panax notoginseng Species 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 22
- 241000229143 Hippophae Species 0.000 claims description 19
- 239000000469 ethanolic extract Substances 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 13
- 235000003935 Hippophae Nutrition 0.000 claims description 13
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 9
- 244000182216 Mimusops elengi Species 0.000 claims description 9
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 9
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 2
- 239000012675 alcoholic extract Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 22
- 210000002966 serum Anatomy 0.000 abstract description 19
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 18
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 14
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 230000004584 weight gain Effects 0.000 abstract description 4
- 235000019786 weight gain Nutrition 0.000 abstract description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- -1 decoction Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition with a function of reducing blood fat, which is characterized by comprising the following Chinese medicinal compositions in parts by weight: 1-12 parts of wolfberry fruit, 1-10 parts of sea buckthorn, 1-9 parts of pseudo-ginseng and 1-10 parts of safflower. The pharmacodynamic experiment result shows that the composition can reduce the contents of serum Total Cholesterol (TC), Triglyceride (TG) and serum low-density lipoprotein cholesterol (LDL-C) of a rat, and has no obvious influence on the weight gain and the serum high-density lipoprotein cholesterol (HDL-C) content of the rat; the preparation prepared by taking the composition as an effective component can obviously reduce TC and TG in serum of a subject, and HDL-C in serum is not obviously changed, the total effective rate is 53.9 percent, and the blood routine, the urine routine, the stool routine, the blood biochemical index and other clinical examinations are not abnormal, so the preparation has good effect of reducing blood fat.
Description
Technical Field
The invention relates to the field of medicines or health-care foods, in particular to a composition with a blood fat reducing function and a preparation method and application thereof.
Background
Hyperlipidemia is a systemic condition, known in modern medicine as dyslipidemia, and is thought to be caused by abnormal fat metabolism or movement, and generally refers to a condition in which one or more lipids in the plasma are above normal levels, such as too high cholesterol (TC) or Triglyceride (TG) in the blood, or too low high density lipoprotein cholesterol (HDL-C). Lipids are bound to proteins in the blood in the form of lipoproteins, and thus hyperlipidemia is usually hyperlipoproteinemia, i.e., elevated serum lipoprotein concentration. Normally, lipid synthesis and decomposition in the human body are in dynamic balance, but lipid metabolism disorders are caused by factors such as diet (high fat, high cholesterol, high carbohydrate food excess, etc.), diseases (obesity, diabetes, etc.), hormones, etc. Hyperlipidemia and lipid metabolism disorder are major risk factors for arterioid sclerosis and coronary atherosclerotic heart disease, and the mortality rate of the latter is high. In the traditional Chinese medicine, the hyperlipidemia belongs to the categories of turbid phlegm and blood stasis, the traditional Chinese medicine theory considers that the basic pathogenesis of the hyperlipidemia is liver and kidney deficiency, endogenous turbid phlegm, qi stagnation and blood stasis, so the basic principle of the traditional Chinese medicine for preventing and treating the hyperlipidemia is tonifying liver and kidney, invigorating spleen and eliminating dampness, and activating blood and dissolving stasis. From the perspective of modern medical treatment, treatment is mainly performed in terms of lowering blood cholesterol (TC) and/or Triglyceride (TG), or increasing high density lipoprotein cholesterol (HDL-C), and the like.
Disclosure of Invention
The invention aims to provide a composition with a function of reducing blood fat, which is characterized by comprising the following Chinese medicinal compositions in parts by weight: 1-12 parts of wolfberry fruit, 1-10 parts of sea buckthorn, 1-9 parts of pseudo-ginseng and 1-10 parts of safflower. The composition of the present invention may be directly ground into powder, or may be an extract prepared by a conventional method in the art, etc. The traditional Chinese medicine used in the composition of the present invention can also be used by directly grinding into powder, extract or other processing forms.
Further, the traditional Chinese medicine composition comprises: 2-8 parts of wolfberry fruit, 2-8 parts of sea buckthorn, 1-6 parts of pseudo-ginseng and 1-6 parts of safflower.
Further, the traditional Chinese medicine composition comprises: 3-6 parts of wolfberry fruit, 2-5 parts of sea buckthorn, 2-4 parts of pseudo-ginseng and 2-4 parts of safflower.
Preferably, the Chinese medicinal composition comprises: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower.
More preferably, the wolfberry fruit, the sea buckthorn and the safflower are aqueous solution extracts, and the pseudo-ginseng is an alcohol aqueous solution extract.
More preferably, the notoginseng is 60% -80% ethanol water extract.
The invention also provides application of the composition in preparing a medicine, a health-care product or food with the function of reducing blood fat.
The invention also provides a medicine, a health product or food of the composition.
Specifically, the aforementioned medicine, health product or food is selected from capsule, tablet, granule, decoction, pill, oral liquid, tincture, syrup, suppository, gel, beverage, capsule, powder, tea, granule, spray or injection, etc.
The invention also provides a preparation method of the composition, which is characterized by comprising the following steps:
water extraction: mixing the wolfberry fruit, the sea buckthorn and the safflower according to a ratio, adding water which is 6-14 times of the total weight of the medicinal materials as an extraction solvent, performing reflux extraction, and filtering to obtain a water extract; preferably extracting under reflux for 1-3 times, each time for 1-3 hours;
alcohol extraction: adding 30-80% ethanol in an amount which is 6-14 times the total weight of the pseudo-ginseng into the pseudo-ginseng as an extraction solvent, performing reflux extraction, and filtering to obtain an ethanol extract; preferably extracting under reflux for 1-3 times, each time for 1-3 hours;
concentrating, drying, crushing and sieving: respectively concentrating the water extract and the alcohol extract under reduced pressure (preferably at 70-80 ℃) until the relative density of the extract is 1.25-1.3 (60 +/-5 ℃), drying under reduced pressure (preferably at-0.07-0.09 MPa relative vacuum degree and 70-80 ℃), crushing, and sieving (such as 60 meshes) to obtain dry extract powder and dry extract powder;
mixing: mixing the water extract dry extract powder and the alcohol extract dry extract powder.
The invention also provides a preparation method of the composition with the function of reducing blood fat, which is characterized by comprising the following steps:
removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, coarsely pulverizing Notoginseng radix, and sieving with 5 mesh sieve; weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae and Carthami flos, adding 10 times of water as extraction solvent, reflux-extracting for 2 times (2 hr each time), filtering, and mixing water extractive solutions; adding 70% ethanol 10 times the total weight of Notoginseng radix as extraction solvent, reflux extracting for 3 times, each for 2 hr, filtering, and mixing the ethanol extractive solutions; concentrating the water extractive solution at 75 deg.C under-0.09 MPa to obtain water extract with relative density of 1.25 at 60 deg.C, and concentrating the ethanol extractive solution at 70 deg.C under-0.08 MPa to obtain ethanol extract with relative density of 1.25 at 60 deg.C; vacuum drying the water extract and ethanol extract at 80 deg.C under relative vacuum degree of-0.07 MPa, respectively, pulverizing, sieving with 60 mesh sieve to obtain water extract dry extract powder and ethanol extract dry extract powder, and mixing.
The invention also provides a preparation method of the medicine with the function of reducing blood fat, which is characterized by comprising the following steps:
mixing the water-extracted dry extract powder, the alcohol-extracted dry extract powder and microcrystalline cellulose 20% of the total weight of all dry extract powder, adding an appropriate amount of ethanol with the volume fraction of 90% to prepare a soft material, granulating by using a 20-mesh sieve, drying at 65 ℃, granulating by using the 20-mesh sieve, adding magnesium stearate 0.5% of the total weight of granules, mixing uniformly, and tabletting; or the like, or, alternatively,
mixing the water-extracted dry extract powder, the alcohol-extracted dry extract powder and lactose accounting for 10% of the total weight of all dry extract powders and dextrin accounting for 10% of the total weight of all dry extract powders, adding an appropriate amount of ethanol accounting for 90% of the volume fraction to prepare a soft material, granulating by using a 20-mesh sieve, drying at 60 ℃, grading dry granules by using 10-mesh and 60-mesh sieves, and subpackaging.
According to the traditional Chinese medicine theory, the invention selects raw materials which are homologous in medicine and food or raw materials which can be used for health-care food, and selectively extracts different effective components by water extraction or alcohol extraction, so the invention is safe and effective and can be eaten for a long time.
The blood fat reducing composition comprises medlar, sea buckthorn, pseudo-ginseng and safflower, wherein the medlar is a dried mature fruit of Lycium barbarum L.of Solanaceae, is sweet and neutral, enters liver and kidney channels, can nourish liver and kidney, and is used for consumptive disease and essence deficiency, soreness and pain of waist and knees, dizziness and tinnitus, blurred vision and the like. Fructus Hippophae is dry mature fruit of Hippophae rhamnoides L. of Elaeagnaceae, sour, astringent, warm, and has effects of invigorating spleen, eliminating phlegm, promoting blood circulation and removing blood stasis, and can be used for treating excessive phlegm, thoracic obstruction, cardialgia, and blood stasis amenorrhea. Notoginseng radix is dried root and rhizome of Panax notoginseng (Burk.) F.H.Chen of Araliaceae, is sweet, slightly bitter, warm in nature, enters liver and stomach channels, has effects of removing blood stasis, stopping bleeding, and relieving swelling and pain, and can be used for treating thoracico-abdominal pain, traumatic injury, and swelling and pain. Carthami flos is dried flower of Carthamus tinctorius L. of Compositae, is pungent and warm in nature, and has effects of invigorating heart and liver channels, promoting blood circulation and removing blood stasis, and can be used for treating thoracic obstruction, cardiodynia, blood stasis and abdominal pain, etc. The whole formula is compatible for use, and has the function of assisting in reducing blood fat. The pharmacodynamic experiment result shows that the composition can reduce the contents of serum Total Cholesterol (TC), Triglyceride (TG) and serum low-density lipoprotein cholesterol (LDL-C) of a rat, and has no obvious influence on the weight gain and the serum high-density lipoprotein cholesterol (HDL-C) content of the rat; the preparation prepared by taking the composition as an effective component can obviously reduce TC and TG in serum of a subject, and HDL-C in serum is not obviously changed, the total effective rate is 53.9 percent, and the blood routine, the urine routine, the stool routine, the blood biochemical index and other clinical examinations are not abnormal, so the preparation has good effect of reducing blood fat.
Detailed Description
As mentioned above, the present invention aims at providing a composition with blood lipid reducing function, a preparation method and applications thereof. The following will specifically describe the contents of the experimental examples.
If the specific conditions are not indicated, the method is carried out according to the conventional conditions or the conditions suggested by manufacturers, and the used raw material medicines or auxiliary materials and the used reagents or instruments are the conventional products which can be obtained commercially.
It is particularly pointed out that the present invention is described in more detail below by means of specific embodiments in order to be able to better understand the solution of the invention and the advantages of its various aspects. The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention.
Hypolipidemic animal function test
1. Experimental Material
1.1 animals
SD rat, male, SPF grade, weight 180 ~ 200g, provided by Yangzhou university's comparative medicine center, experimental animals production license number: SCXK (Su) 2014-. The temperature of an animal laboratory is 22-25 ℃, and the relative humidity is 55-70%.
1.2 drugs and reagents
OLYMPUSAU400 model full-automatic biochemical analyzer; triglyceride (TG) kit, Total Cholesterol (TC) kit, high density lipoprotein cholesterol (HDL-C) kit, and low density lipoprotein cholesterol (LDL-C) kit, AUTECDIAGNOSTICA, Germany;
general feed and high fat feed (90% basal feed, 1.2% cholesterol, 8% lard, 0.2% sodium cholate, appropriate amount of casein and sodium hydrogen phosphate 0.6%), purchased from oxepin feed ltd of beijing family;
the daily recommended dosage of crude drug is 11g/60kg BW.
2. Experimental methods
2.1 Experimental methods
According to an accessory 6-auxiliary hypolipidemic functional test method of a national food and drug insurance No. [2012]107 notification about 9 health-care functional evaluation methods such as a printing antioxidant functional evaluation method issued by the State food and drug administration, a mixed-type hyperlipemia model method is adopted for a tested sample. Rats were fed maintenance feed in an animal laboratory and observed for 5 days, and were randomly divided into 2 groups by body weight, 10 rats were given maintenance feed as a blank control group, and 50 rats were given model feed as a model control group. Weigh once a week. After the model control group is fed with the model feed for 2 weeks, the blank control group and the model control group do not fast and blood is collected from the inner canthus of the eyes of the rats to measure various blood fat observation indexes. Model control groups of rats were divided into 5 groups of 10 rats each by a stratified random sampling method based on the TC level, and the rats TG, HDL-C, LDL-C and initial body weight of each group were adjusted to be as uniform as possible. After the start of the experiment, the other groups except the blank control group were fed with model feed, and simultaneously, rats in each experimental group were administered the test solution through oral gavage, and two control groups were administered pure water through gavage, and the gavage amount was 1.0mL/100 g.BW. The gavage is carried out once a day for 30 days continuously. Weigh once a week and adjust gavage based on body weight. The rats were bled without fasting from the experiment to day 31 to measure serum TC, TG, HDL-C and LDL-C contents (all by enzyme reagent-endpoint method).
2.2 grouping and dose setting
The recommended intake of the human body in the invention is 11g of crude drugs per person per day, and each person is measured by 60kg of weight, which is equivalent to 0.183g of crude drugs per day per kg of weight. The medium dose of the rats was determined to be 10 times the recommended dose for human, i.e., the daily intake of rats was 1.83g crude drug/kg & BW. The test substance is prepared by deionized water, and the rat test substance solution is administered by intragastric administration once a day, wherein the intragastric volume is calculated according to 1.0mL/100 g.BW. At the same time, the placebo and model controls were gavaged with a comparable volume of deionized water. And (3) continuously feeding the maintenance feed to the blank control group, continuously feeding the model control group and the dry paste powder group to the model feed, continuously feeding for 30 days, regularly weighing the body weight, collecting blood without fasting at the end of the experiment, separating the blood serum as soon as possible after the blood collection, and measuring the TC, TG and HDL-C, LDL-C levels of the blood serum.
3. Basis of result determination
In four indexes of serum total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, compared with a model control group, the serum total cholesterol or low-density lipoprotein cholesterol is reduced, the triglyceride is reduced, the difference is significant, and the serum high-density lipoprotein cholesterol of each group is not significantly lower than that of the model control group, so that the positive animal experiment result of the function of assisting in reducing blood fat of the tested sample can be judged.
4. Results of the experiment
4.1 Effect of samples on rat body weight
TABLE 1 weight changes of rats in each group before and after the experiment
As shown in Table 1, the differences of the weights of the rats in each group before the experiment are not significant (P > 0.05); the weight and weight gain of rats in each group are not significant compared with those of the model control group by the 30 th day of the experiment (P > 0.05). The experimental group showed no obvious effect on the weight gain of the rats fed with model feed.
4.2 Effect of samples on rat TC, TG, HDL-C and LDL-C
TABLE 2 serum TC, TG, HDL-C and LDL-C assay results of various groups of rats
Note: p <0.05, P <0.01, compared to the blank control group; compared with the model control group, a represents P <0.01, and b represents P < 0.05.
As can be seen from table 2, examples 1, 2, 3 and 4 all have the function of reducing blood lipid, and the differences from the model control group are significant (P < 0.05); the effects of examples 1 to 3 were more remarkable.
Blood fat reducing human body test
The sample obtained in example 6 (3.67g crude drug/bag) was applied to a human feeding trial for a hyperlipidemic population for 45 consecutive days.
Grouping: the initial test group had 56 volunteers in the test, and the final test group and the control group had 52 and 51 subjects for final statistics, respectively. Before eating, the age, mental condition, sleep condition, diet condition and the like of the test group (1.5g, adults are taken 3 times a day, 1 bag each time, and the placebo is the same as the test group) and the control group are basically consistent, and the examinations of blood pressure, blood routine, blood biochemical index and the like are not abnormal; the chest fluoroscopy, electrocardiogram and abdomen B-ultrasonic examination results of two groups of people have no obvious abnormality, and the serum TC, TG, HDL-C and LDL-C have no obvious difference and are comparable.
TABLE 3 serum TC comparison of two groups of people before and after a test meal
TABLE 4 comparison of serum TG in two groups of people before and after a test meal
TABLE 5 comparison of serum HDL-C in two groups of populations before and after a test meal
TABLE 6 effective conditions of the samples for the hyperlipidemic population
Note: the total effective rate means that TC and TG are effective, and the total effective rate (%) is equal to the total effective number/tested person number multiplied by 100%.
After the test food, the heart rate, the blood pressure, the blood routine, the urine routine, the stool routine, the blood biochemical indexes, the chest penetration, the electrocardiogram and the B-ultrasonic examination of the testee are all within normal value ranges, and the testee has no adverse reactions such as nausea, flatulence, diarrhea, allergy and the like in the test process.
The test result shows that the invention has the efficacy of assisting in reducing blood fat.
Example 1
Removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, pulverizing Notoginseng radix, and sieving with 5 mesh sieve. Weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae and Carthami flos, adding 10 times of water as extraction solvent, reflux-extracting for 2 times (2 hr each time), filtering, and mixing water extractive solutions; adding 70% ethanol 10 times of the total weight of the raw materials as extraction solvent into the Notoginseng radix coarse powder, reflux extracting for 3 times, each for 2 hr, filtering, and mixing the ethanol extractive solutions; concentrating the water extractive solution at 75 deg.C under-0.09 MPa to obtain water extract with relative density of 1.25 at 60 deg.C, and concentrating the ethanol extractive solution at 70 deg.C under-0.08 MPa to obtain ethanol extract with relative density of 1.25 at 60 deg.C; vacuum drying the water extract and ethanol extract at 80 deg.C under relative vacuum degree of-0.07 MPa, respectively, pulverizing, sieving with 60 mesh sieve to obtain water extract dry extract powder and ethanol extract dry extract powder, and mixing.
Example 2
Removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, pulverizing Notoginseng radix, and sieving with 5 mesh sieve. Weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae and Carthami flos, adding 8 times of water as extraction solvent, reflux-extracting for 1 time (1 hr each time), filtering, and mixing water extractive solutions; adding 60% ethanol 8 times the total weight of the raw materials into the Notoginseng radix coarse powder as extraction solvent, reflux extracting for 1 time, each time for 1 hr, filtering, and mixing the ethanol extractive solutions; concentrating the water extractive solution at 70 deg.C under-0.07 MPa to obtain water extract with relative density of 1.25 at 60 deg.C, and concentrating the ethanol extractive solution at 70 deg.C under-0.07 MPa to obtain ethanol extract with relative density of 1.25 at 60 deg.C; vacuum drying the water extract and ethanol extract at 70 deg.C under relative vacuum degree of-0.07 MPa, respectively, pulverizing, sieving with 60 mesh sieve to obtain water extract dry extract powder and ethanol extract dry extract powder, and mixing.
Example 3
Removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, pulverizing Notoginseng radix, and sieving with 5 mesh sieve. Weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae and Carthami flos, adding 12 times of water as extraction solvent, reflux-extracting for 3 times (each for 3 hr), filtering, and mixing water extractive solutions; adding 80% ethanol 12 times the total weight of the raw materials as extraction solvent into the Notoginseng radix coarse powder, reflux extracting for 3 times, each for 3 hr, filtering, and mixing the ethanol extractive solutions; concentrating the water extractive solution at 80 deg.C under-0.09 MPa to obtain water extract with relative density of 1.30 at 65 deg.C, and concentrating the ethanol extractive solution at 80 deg.C under-0.09 MPa to obtain ethanol extract with relative density of 1.30 at 65 deg.C; vacuum drying the water extract and ethanol extract at 80 deg.C under relative vacuum degree of-0.09 MPa, respectively, pulverizing, sieving with 60 mesh sieve to obtain water extract powder and ethanol extract powder, and mixing.
Example 4
Removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, pulverizing Notoginseng radix, and sieving with 5 mesh sieve. Weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae, Carthami flos, and Notoginseng radix coarse powder, adding 10 times of water as extraction solvent, reflux-extracting for 2 times (2 hr each time), filtering, and mixing water extractive solutions; concentrating the water extractive solution at 75 deg.C under-0.09 MPa to obtain concentrated extract with relative density of 1.25 at 65 deg.C, vacuum drying at 80 deg.C under-0.09 MPa, pulverizing, and sieving with 60 mesh sieve to obtain dry extract powder.
Example 5
Mixing the water-extracted dry extract powder, the alcohol-extracted dry extract powder and microcrystalline cellulose which accounts for 20% of the total weight of all the dry extract powders obtained in the embodiment 1 uniformly, adding a proper amount of ethanol with the volume fraction of 90% to prepare soft materials, granulating by using a 20-mesh sieve, drying at 65 ℃, grading the dry granules by using the 20-mesh sieve, adding magnesium stearate which accounts for 0.5% of the total weight of the granules, uniformly mixing, tabletting and coating to obtain coated tablets (1.83g crude drugs/tablet).
Example 6
Mixing the water extract dry extract powder, the alcohol extract dry extract powder and lactose accounting for 10% of the total weight of all dry extract powders and dextrin accounting for 10% of the total weight of all dry extract powders, adding an appropriate amount of ethanol accounting for 90% of the volume fraction to prepare soft materials, granulating by using a 20-mesh sieve, drying at 60 ℃, grading dry granules by using 10-mesh and 60-mesh sieves, and subpackaging to obtain granules (3.67g crude drugs/bag).
Example 7
Mixing the water-extracted dry extract powder, the alcohol-extracted dry extract powder and corn starch accounting for 20% of the total weight of all the dry extract powders obtained in the embodiment 1 uniformly, adding a proper amount of ethanol with the volume fraction of 90% to prepare soft materials, granulating by using a 24-mesh sieve, drying at 60 ℃, grading the dry granules by using the 24-mesh sieve, adding silicon dioxide accounting for 0.5% of the total weight of the granules, uniformly mixing, and filling to obtain capsules (0.92g crude drugs/granules).
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (10)
1. The composition with the function of reducing blood fat is characterized in that the traditional Chinese medicine composition comprises the following components in parts by weight: 1-12 parts of wolfberry fruit, 1-10 parts of sea buckthorn, 1-9 parts of pseudo-ginseng and 1-10 parts of safflower.
2. The composition of claim 1, wherein the Chinese medicinal composition comprises: 2-8 parts of wolfberry fruit, 2-8 parts of sea buckthorn, 1-6 parts of pseudo-ginseng and 1-6 parts of safflower.
3. The composition of claim 1, wherein the Chinese medicinal composition comprises: 3-6 parts of wolfberry fruit, 2-5 parts of sea buckthorn, 2-4 parts of pseudo-ginseng and 2-4 parts of safflower.
4. The composition according to any one of claims 1 to 3, wherein the wolfberry fruit, the sea buckthorn and the safflower are aqueous extracts and the notoginseng is an aqueous alcoholic extract.
5. The composition as claimed in claim 4, wherein the notoginseng is 60% -80% ethanol aqueous extract.
6. Use of the composition according to any one of claims 1 to 5 for the preparation of a medicament, health product or food having hypolipidemic effect.
7. A pharmaceutical, nutraceutical or food product comprising a composition according to any of claims 1 to 5.
8. A process for the preparation of a composition according to any one of claims 1 to 5, comprising the steps of:
water extraction: mixing the wolfberry fruit, the sea buckthorn and the safflower according to a ratio, adding water which is 6-14 times of the total weight of the medicinal materials as an extraction solvent, performing reflux extraction, and filtering to obtain a water extract;
alcohol extraction: adding 30-80% ethanol in an amount which is 6-14 times the total weight of the pseudo-ginseng into the pseudo-ginseng as an extraction solvent, performing reflux extraction, and filtering to obtain an ethanol extract;
concentrating, drying, crushing and sieving: concentrating the water extractive solution and ethanol extractive solution under reduced pressure, drying under reduced pressure, pulverizing, and sieving to obtain water extract dry extract powder and ethanol extract dry extract powder;
mixing: mixing the water extract dry extract powder and the alcohol extract dry extract powder.
9. A preparation method of a composition with a function of reducing blood fat is characterized by comprising the following steps:
removing impurities from fructus Lycii, fructus Hippophae, Notoginseng radix, and Carthami flos, coarsely pulverizing Notoginseng radix, and sieving with 5 mesh sieve; weighing the following raw materials in parts by weight: 4 parts of medlar, 3 parts of sea buckthorn, 2 parts of pseudo-ginseng and 2 parts of safflower; mixing fructus Lycii, fructus Hippophae and Carthami flos, adding 10 times of water as extraction solvent, reflux-extracting for 2 times (2 hr each time), filtering, and mixing water extractive solutions; adding 70% ethanol 10 times the total weight of Notoginseng radix as extraction solvent, reflux extracting for 3 times, each for 2 hr, filtering, and mixing the ethanol extractive solutions; concentrating the water extractive solution at 75 deg.C under-0.09 MPa to obtain water extract with relative density of 1.25 at 60 deg.C, and concentrating the ethanol extractive solution at 70 deg.C under-0.08 MPa to obtain ethanol extract with relative density of 1.25 at 60 deg.C; vacuum drying the water extract and ethanol extract at 80 deg.C under relative vacuum degree of-0.07 MPa, respectively, pulverizing, sieving with 60 mesh sieve to obtain water extract dry extract powder and ethanol extract dry extract powder, and mixing.
10. A preparation method of a medicine with the function of reducing blood fat is characterized by comprising the following steps:
mixing the water-extracted dry extract powder, the alcohol-extracted dry extract powder and 10% of lactose and 10% of dextrin which are respectively 10% of the total weight of all the dry extract powders prepared by the method of claim 9 uniformly, adding a proper amount of ethanol with the volume fraction of 90% to prepare a soft material, granulating by using a 20-mesh sieve, drying at 60 ℃, grading dry granules by using a 10-mesh sieve and a 60-mesh sieve, and subpackaging.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910942769.8A CN110664903A (en) | 2019-09-30 | 2019-09-30 | Composition with blood fat reducing function and preparation method and application thereof |
| PCT/CN2020/094674 WO2021063016A1 (en) | 2019-09-30 | 2020-06-05 | Composition with hypolipidemic function, preparation method therefor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910942769.8A CN110664903A (en) | 2019-09-30 | 2019-09-30 | Composition with blood fat reducing function and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110664903A true CN110664903A (en) | 2020-01-10 |
Family
ID=69080558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910942769.8A Withdrawn CN110664903A (en) | 2019-09-30 | 2019-09-30 | Composition with blood fat reducing function and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110664903A (en) |
| WO (1) | WO2021063016A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021063016A1 (en) * | 2019-09-30 | 2021-04-08 | 江苏康仁医药科技开发有限公司 | Composition with hypolipidemic function, preparation method therefor and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110664903A (en) * | 2019-09-30 | 2020-01-10 | 江苏康缘药业股份有限公司 | Composition with blood fat reducing function and preparation method and application thereof |
-
2019
- 2019-09-30 CN CN201910942769.8A patent/CN110664903A/en not_active Withdrawn
-
2020
- 2020-06-05 WO PCT/CN2020/094674 patent/WO2021063016A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021063016A1 (en) * | 2019-09-30 | 2021-04-08 | 江苏康仁医药科技开发有限公司 | Composition with hypolipidemic function, preparation method therefor and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021063016A1 (en) | 2021-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN103520551B (en) | A kind of damp-heat constitution health food and preparation method thereof | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN110664903A (en) | Composition with blood fat reducing function and preparation method and application thereof | |
| CN109157584B (en) | Composition with auxiliary blood fat reducing function and preparation method and application thereof | |
| CN115137770B (en) | Preparation method of traditional Chinese medicine product with efficacy of reducing blood fat and blood pressure | |
| CN104189349B (en) | Traditional Chinese medicine composition for treating oligomenorrhea | |
| CN101020016B (en) | Medicine for treating fracture and injured tendon and its preparation | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN114145374A (en) | Astragalus membranaceus and corn stigma composite tea and preparation method and application thereof | |
| CN101062204B (en) | Method for preparing capsule made from asarum, scutellaria and so on and the capsule prepared by using said method | |
| WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN104055963B (en) | A kind of fat reducing Chinese medicine composition and preparation method | |
| CN107095979B (en) | Traditional Chinese medicine composition suitable for treating hyperlipidemia, preparation method and application thereof | |
| CN105726921A (en) | Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CH699627B1 (en) | Composition of Chinese medicinal herbs for treating apoplexy, hemiplegia, myocardial ischemia and Kardiodynie, and processes for their preparation. | |
| CN100358553C (en) | Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof | |
| CN109646405A (en) | A kind of monkey mushroom granule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200110 |